Agios Pharmaceuticals, Inc. (AGIO) NASDAQ
28.17
+0.0044(+0.02%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Agios Pharmaceuticals, Inc.
Address
88 Sidney Street
Cambridge, MA 02139-4169
United States of America (the)
Phone
617 649 8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
486
First IPO Date
July 24, 2013
Key Executives
| Name | Title | Pay | Year Born |
| Brian Goff | Chief Executive Officer & Director | 1.45M | 1969 |
| Shin-San Su | Co-Founder | 50,000 | 1956 |
| Craig Thompson | Co-Founder | 50,000 | 1953 |
| Tak Wah Mak FRSC | Co-Founder | 50,000 | 1946 |
| Lewis Clayton Cantley | Co-Founder | 50,000 | 1949 |
| James William Burns | Chief Legal Officer | 780,510 | 1978 |
| Cecilia Jones | Chief Financial Officer | 791,835 | 1975 |
| Tsveta Milanova | Chief Commercial Officer | 836,643 | 1978 |
| Sarah Gheuens | Chief Medical Officer and Head of Research & Development | 887,232 | 1980 |
| Krishnan Viswanadhan | Chief Corporate Development & Strategy Officer | 931,509 | 1979 |
| Steven Vickers | Vice President of Sales | 0 | N/A |
| T. J. Washburn | Vice President, Controller & Principal Accounting Officer | 0 | 1982 |
| Clive Patience | Chief Technical Operations Officer | 0 | 1964 |
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
